Log In
BCIQ
Print this Print this
 

pibrentasvir (ABT-530)

  Manage Alerts
Collapse Summary General Information
Company AbbVie Inc.
DescriptionNext-generation HCV NS5A protein inhibitor
Molecular Target HCV NS5A protein
Mechanism of ActionHCV non-structural protein 5A inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase III
Standard IndicationHepatitis C virus (HCV)
Indication DetailsTreat chronic HCV genotype 1, 2, 3, 4, 5 or 6 infection; Treat chronic HCV genotype 1, 2, 4, 5 or 6 infection; Treat chronic HCV genotype 2 infection; Treat chronic HCV genotype 3 infection; Treat chronic HCV genotype 4, 5 or 6 infection; Treat chronic HCV genotypes 1 and 4-6 infection in patients who failed a prior direct-acting antiviral (DAA)-containing therapy; Treat chronic HCV genotypes 2 and 3 infection; Treat chronic HCV infection; Treat HCV genotype 1 infection
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today